Comprehensive Analysis and Functional Characteristics of Differential Expression of N6-Methyladenosine Methylation

Lei Wan1,2, Jian Liu1,2, Chuanbing Huang1

  • 1The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230038, China.

Mediators of Inflammation
|November 4, 2022
PubMed

Insights

N6-methyladenosine (m6A) modification plays a role in rheumatoid arthritis (RA) development. This study identified key m6A-modified genes and pathways involved in RA synovial inflammation, offering potential therapeutic targets.

Area of Science:

  • Epigenetics and Molecular Biology
  • Immunology and Rheumatology

Background:

  • N6-methyladenosine (m6A) is the most common mRNA modification in eukaryotes, linked to immune diseases.
  • The specific role of m6A methylation in rheumatoid arthritis (RA) pathogenesis remains largely unexplored.

Purpose of the Study:

  • To investigate the role of m6A methylation-related messenger RNAs (mRNAs) in RA development.
  • To identify potential clinical applications and therapeutic targets for RA treatment based on m6A modification.

Main Methods:

  • Utilized high-throughput sequencing, methylated RNA immunoprecipitation (MeRIP-seq), and RNA sequencing (RNA-seq) on synovial tissue from RA patients.
  • Analyzed the correlation between m6A-modified genes, RA inflammation, macrophage activation, and signaling pathways (MAPK, PI3K-Akt).
  • Validated findings through animal experiments assessing m6A modification patterns and protein expression in an RA model.

Main Results:

  • Identified 120 genes with significant changes in both m6A modification and mRNA expression in RA.
  • Observed decreased expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) mRNA and protein in RA patients.
  • Found increased expression of SHC-binding protein 1 (SHCBP1) and neurexophilin-3 (NXPH3) mRNA, alongside elevated M1 macrophages and activated MAPK/PI3K-Akt signaling in RA.

Conclusions:

  • Revealed a distinct pattern of differential m6A methylation in RA synovial tissue.
  • Concluded that m6A modification is significantly associated with the occurrence and progression of RA synovial inflammation.
  • Highlighted m6A-modifying genes as potential novel therapeutic targets for RA treatment.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.0K
RNA Editing02:23

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.1K